<DOC>
	<DOCNO>NCT01085331</DOCNO>
	<brief_summary>The research trial test experimental treatment pimasertib ( MSC1936369B ) combination FOLFIRI , second-line treatment metastatic K Ras mutate colorectal cancer subject . The study run two part : Part 1 , Safety Run-in Part : Will determine maximum tolerate dose recommend Phase 2 dose ( RP2D ) pimasertib combine FOLFIRI second-line treatment subject metastatic K Ras mutate colorectal cancer . Part 2 Phase 2 Randomised Part : Will assess anti-tumor activity pimasertib combine FOLFIRI compare FOLFIRI placebo second-line treatment metastatic K Ras mutate colorectal cancer subject . Phase I Is open label dose escalation `` 3+3 '' cohort , non-randomized , safety Phase II double blind randomize safety/efficacy</brief_summary>
	<brief_title>MEK Inhibitor MSC1936369B Plus FOLFIRI Second Line K-Ras Mutated Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>For Safety Runin Part 2 Phase 2 Randomised Part Histologically confirm KRas mutate colon/rectum cancer Subject 's disease must progress firstline treatment metastatic disease oxaliplatin fluoropyrimidines base chemotherapy without bevacizumab Evidence metastatic measurable disease trial entry per Response Evaluation Criteria Solid Tumors . Complete tumor assessment perform within 14 day prior first trial drug administration Male/female subject age great equal ( &gt; = ) 18 year Subject read understood inform consent form Women childbearing potential must negative blood pregnancy test screen visit . Subjects partner must willing avoid pregnancy trial For Safety Runin Part 2 Phase 2 Randomised Part Bone marrow impairment Renal impairment Liver function liver cell integrity abnormality History central nervous system ( CNS ) metastases History difficulty swallowing , malabsorption chronic gastrointestinal disease Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) great ( &gt; ) 1 Known human immunodeficiency virus ( HIV ) positivity , active hepatitis C , active hepatitis B Has receive extensive prior radiotherapy 30 percent ( % ) bone marrow reserve , prior bone marrow/stem cell transplantation Has receive chemotherapy , investigational drug , participate another clinical trial within past 4 week prior trial first drug administration Has history significant medical disease Past current history ( within last 2 year prior inclusion ) malignancies except indication study Has significant cardiac conduction abnormality and/or pacemaker Is pregnant nurse female Has retinal degenerative disease , history uveitis , history retinal vein occlusion Other significant disease Investigator 's opinion would exclude subject trial Known hypersensitivity trial treatment ( ) diluent ( applicable ) , include placebo comparator drug ( ) Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mek Inhibitor</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>K-Ras Mutation</keyword>
	<keyword>Phase II</keyword>
	<keyword>Second line K-Ras mutate metastatic colorectal cancer</keyword>
</DOC>